LRRK2 and the stress response: Interaction with MKKs and JNK-interacting proteins

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 68-75

  Hsu, C H ^a   Chan, D ^a   Wolozin, B ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C jun NH2 terminal kinase; Immunoprecipitation; MAP kinase; Parkinson's disease; Scaffold proteins

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; SCAFFOLD PROTEIN; STRESS ACTIVATED PROTEIN KINASE INTERACTING PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE INTERACTING PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE INTERACTING PROTEIN 3; STRESS ACTIVATED PROTEIN KINASE INTERACTING PROTEIN 4; UNCLASSIFIED DRUG;

CONFERENCE PAPER; ENZYME LOCALIZATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; STRESS;

ANALYSIS OF VARIANCE; CELL LINE, TRANSFORMED; HUMANS; IMMUNOPRECIPITATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MUTATION; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SUBCELLULAR FRACTIONS; TRANSFECTION;

EID: 76749094597     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000285509     Document Type: Conference Paper

References (38)

1. Biskup S, Gerlach M, Kupsch A, Reichmann H, Riederer P, Vieregge P, Wullner U, Gasser T: Genes associated with Parkinson syndrome. J Neurol 2008; 255(suppl 5):8-17.
2. Taylor JP, Mata IF, Farrer MJ: LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med 2006; 12: 76-82.
3. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB: LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424-425.
4. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A: LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006; 354: 422-423.
5. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-607.
6. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez- Tur J, Wood NW, Singleton AB: Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
7. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P: RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400-410.
8. Meylan E, Tschopp J: The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 2005; 30: 151-159.
9. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT: The Parkinson disease protein leucinerich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 2009; 29: 1011-1016.
10. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL: Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006; 60: 557-569.
11. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM: Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007; 16: 223-232.
12. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR: The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 2007; 357: 668-671.
13. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR: Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA 2008; 105: 1499-1504.
14. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A, Thomas KJ, Baekelandt V, Cookson MR: The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 2008; 283: 16906-16914.
15. Klein CL, Rovelli G, Springer W, Schall C, Gasser T, Kahle PJ: Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem 2009; 111: 703-715.
16. Sen S, Webber PJ, West AB: Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem 2009; 284: 36346-36356.
17. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A: Structure of the Roc-COR domain tandem of C. tepidum , a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 2008; 27: 2239-2249.
18. Wang LH, Besirli CG, Johnson EM Jr: Mixedlineage kinases: a target for the prevention of neurodegeneration. Annu Rev Pharmacol Toxicol 2004; 44: 451-474.
19. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005; 102: 16842-16847.
20. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR: Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006; 23: 329-341.
21. Greggio E, Lewis PA, van der Brug MP, Ahmad R, Kaganovich A, Ding J, Beilina A, Baker AK, Cookson MR: Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem 2007; 102: 93-102.
22. Biskup S, West AB: Zeroing in on LRRK2- linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 2009; 1792: 625-633.
23. Greggio E, Cookson MR: Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009; 1: e00002.
24. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B: Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 2008; 27: 2432-2443.
25. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR: LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007; 405: 307-317.
26. Gloeckner CJ, Schumacher A, Boldt K, Ueffing M: The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 2009; 109: 959-968.
27. Hsu CH, Chan D, Greggio E, Guillily MD, Segal L, Saha S, Cookson MR, Wolozin B: Association of Parkinson's disease-related protein LRRK2 with MKK6 stimulates their mutual membrane translocation. J Neurochem 2010; Jan 7, Epub ahead of print.
28. Whitmarsh AJ: The JIP family of MAPK scaffold proteins. Biochem Soc Trans 2006; 34: 828-832.
29. Kelkar N, Standen CL, Davis RJ: Role of the JIP4 scaffold protein in the regulation of mitogen- activated protein kinase signaling pathways. Mol Cell Biol 2005; 25: 2733-2743.
30. Verhey KJ, Meyer D, Deehan R, Blenis J, Schnapp BJ, Rapoport TA, Margolis B: Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol 2001; 152: 959-970.
31. Zerbinatti CV, Cordy JM, Chen CD, Guillily M, Suon S, Ray WJ, Seabrook GR, Abraham CR, Wolozin B: Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein. Mol Neurodegener 2008; 3: 5.
32. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Alexander P, Choi P, Palacino J, Hardy J, Wolozin B:γ-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999; 19: 5782-5791.
33. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwatsubo T, Moore L, Goldstein L, Cookson M, Wolozin B: LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 2009; 29: 9210-9218.
34. Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E: alpha- Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J Biol Chem 2002; 277: 11465-11472.
35. Scheinfeld MH, Ghersi E, Davies P, D'Adamio L: Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1. J Biol Chem 2003; 278: 42058-42063.
36. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ: Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006; 67: 1506-1508.
37. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA: Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 2005; 102: 18676-18681.
38. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT: Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 2008; 105: 1048-1056.